

RESERVES AND BALANCE AVAILABLE FOR ALLOCATION

Table 6 provides a summary of carryover balances as of September 30, 2013, and anticipated claims on those balances.

Prudent operations also require that a reserve be kept aside for potential refunds. For that purpose a total of \$5,000,000 is being set aside. An additional \$27,590,900 is set aside for the Agency's move to White Oak. Additionally, the amount of collections appropriated for FY 2013 but sequestered under the Balanced Budget and Emergency Deficit Control Act of 1985, as amended by the Budget Control Act of 2011, totaled \$34,166,383; these funds are deemed unavailable for obligation.¹ Subtracting these four reserve amounts from carryover balances leaves a total remaining carryover balance of \$173,405,596.

TABLE 6: SUMMARY STATEMENT OF PRESCRIPTION DRUG USER FEE CARRYOVER BALANCE AND ANTICIPATED CLAIMS ON THEM AS OF SEPTEMBER 30, 2013

STATUS OF CARRYOVER FUNDS	AMOUNT
Total Carryover Balance	\$240,162,879
Reserve for Future Collection Offset	(\$0)
Reserve for Refunds	(\$5,000,000)
Reserve for move to White Oak	(\$27,590,900)
Reserve for FY 2013 Sequestered Collections	(\$34,166,383)
Remaining Carryover Balance	\$173,405,596

PDUFA V authorizes FDA to have up to three months of available carryover balance at the end of FY 2017. FDA currently estimates that operations will require approximately \$71,003,000 per month for the first three months of FY 2018, and that the remaining carryover balance available (\$173.4 million) could fund 2.4 months of operations in FY 2018. The current status of FDA's ability to access and obligate the funds in the remaining carryover balance remains uncertain.

¹ This report provides information on user fee balances as of the end of FY 2013. We note that, after the end of FY 2013, Congress enacted legislation that makes the FY 2013 sequestered user fees available for obligation by FDA. See section 747 of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014 (Public 113-76).